Severe Asthma

In the UK, over 8 million people, or approximately 12% of the population, have been diagnosed with asthma.¹

Someone with ‘severe asthma’ has a specific type of asthma which is difficult to control with optimised inhaled therapy.²

Severe asthma is a complex condition and may be driven by different inflammatory pathways.³

8% of asthma patients in primary care potentially have severe asthma.

Importance of identifying patients in primary care

Patients with severe forms of asthma face substantial burden of illness, marked reductions in quality of life, and require a significant amount of health resource.⁵

Primary Care clinicians can play an important role in identifying patients that potentially have severe asthma as it can be a life-threatening and debilitating condition that requires expert input to confirm the diagnosis and appropriate management.⁵

SPECTRA: Identification of SusPECTed seveRe Asthma in Adults

SPECTRA primary care clinical system resources have been developed to help identify adults with potential severe asthma, optimise treatment and, where required, refer them to severe asthma centres.

Identify patients with suspected severe asthma

Review & refer appropriate patients needing further input

Treatment escalation to severe asthma centres
SPECTRA GP Clinical System Resources

AstraZeneca have worked in collaboration with the Accelerated Access Collaborative for input into the development of SPECTRA.

**Searches & Alerts**

- EMIS, SystmOne & Vision

**Referral Extract Template**

A referral extract template to facilitate the automatic collection of data and medication as part of the referral process.

**Impact Reporting**

- Practice level and local health economy dashboards.
- Downloadable baseline and follow-up PDF reports (if required) to measure continual review and impact of the service.

---

### Accessing SPECTRA

To access clinical system resources and reporting for your Healthcare Organisation register on [www.suspected-severe-asthma.co.uk](http://www.suspected-severe-asthma.co.uk)

**support@suspected-severe-asthma.co.uk**

**01332 546 909**

This Medical Educational Goods and Service is organised and funded by AstraZeneca and delivered by Oberoi Consulting.

---

### References